Multimedialna platforma wiedzy medycznej Internetowa Księgarnia Medyczna Kalendarium Konferencji
Folia Histochemica et Cytobiologica
MENU
Shortcuts Submit an article Author Guidelines Ahead of Print Reviewers 2023 Editorial Board

open access

Vol 59, No 4 (2021)
Original paper
Submitted: 2021-08-13
Accepted: 2021-12-02
Published online: 2021-12-09
View PDF Download PDF file
Get Citation

Soyasaponin Ag inhibits triple-negative breast cancer progression via targeting the DUSP6/MAPK signaling

Shoucheng Huang1, Ping Huang2, Huazhang Wu3, Song Wang1, Guodong Liu1
DOI: 10.5603/FHC.a2021.0029
·
Pubmed: 34970732
·
Folia Histochem Cytobiol 2021;59(4):291-301.
Affiliations
  1. College of Life and Health Science, Anhui Science and Technology University, Fengyang 233100, Anhui, China
  2. College of Chemical and Materials Engineering, Anhui Science and Technology University, Fengyang 233100, Anhui, China
  3. School of Life Science, Anhui Province Key Laboratory of Translational Cancer Research, Bengbu Medical College, Bengbu 233030, Anhui, China

open access

Vol 59, No 4 (2021)
ORIGINAL PAPERS
Submitted: 2021-08-13
Accepted: 2021-12-02
Published online: 2021-12-09

Abstract

Introduction. Soyasaponins are triterpenoid glycosides discovered in soybean and have anti-cancer properties. Soyasaponin A was reported to repress estrogen-insensitive breast cancer cell proliferation. This study intends to explore the role of one isomer of soyasaponin A, i.e. soyasaponin Ag (Ssa Ag), in triple-negative breast cancer (TNBC) development.

Material and methods. Bioinformatic databases were used to predict DUSP6 expression in breast cancer (BC) as well as the correlation between the expression of DUSP6 (or MAPK1, MAPK14) with the prognosis of patients with BC. The expression of DUSP6/MAPK signaling-related genes (DUSP6, MAPK1, and MAPK14) in TNBC cell lines was assessed via Western blot analysis and RT-qPCR. Levels of cell apoptosis proteins (Bax and Bcl-2) in TNBC cells were assessed via Western blot analysis. CCK-8 assay, colony formation assay, and flow cytometry analysis were conducted for the measurement of TNBC cell growth and apoptosis. In vivo xenograft assay was employed for investigating the biological influence of Ssa Ag on tumor growth.

Results. The poor prognosis of BC patients was linked to the aberrant expression of DUSP6/MAPK pathway
genes. Low expression of DUSP6 or high expression of MAPK1 (or MAPK14) was correlated to poor prognosis. DUSP6 was downregulated while MAPK1 and MAPK14 were upregulated in TNBC cells versus normal cells. Ssa Ag upregulated DUSP6 expression while downregulated MAPK1 and MAPK14 expression, inhibiting the MAPK signaling pathway. Additionally, Ssa Ag promoted in vitro TNBC cell apoptosis and restrained cell growth, and repressed in vivo tumor growth.

Conclusions. Ssa Ag inhibited TNBC progression via upregulating DUSP6 and inactivating the MAPK signaling pathway.

Abstract

Introduction. Soyasaponins are triterpenoid glycosides discovered in soybean and have anti-cancer properties. Soyasaponin A was reported to repress estrogen-insensitive breast cancer cell proliferation. This study intends to explore the role of one isomer of soyasaponin A, i.e. soyasaponin Ag (Ssa Ag), in triple-negative breast cancer (TNBC) development.

Material and methods. Bioinformatic databases were used to predict DUSP6 expression in breast cancer (BC) as well as the correlation between the expression of DUSP6 (or MAPK1, MAPK14) with the prognosis of patients with BC. The expression of DUSP6/MAPK signaling-related genes (DUSP6, MAPK1, and MAPK14) in TNBC cell lines was assessed via Western blot analysis and RT-qPCR. Levels of cell apoptosis proteins (Bax and Bcl-2) in TNBC cells were assessed via Western blot analysis. CCK-8 assay, colony formation assay, and flow cytometry analysis were conducted for the measurement of TNBC cell growth and apoptosis. In vivo xenograft assay was employed for investigating the biological influence of Ssa Ag on tumor growth.

Results. The poor prognosis of BC patients was linked to the aberrant expression of DUSP6/MAPK pathway
genes. Low expression of DUSP6 or high expression of MAPK1 (or MAPK14) was correlated to poor prognosis. DUSP6 was downregulated while MAPK1 and MAPK14 were upregulated in TNBC cells versus normal cells. Ssa Ag upregulated DUSP6 expression while downregulated MAPK1 and MAPK14 expression, inhibiting the MAPK signaling pathway. Additionally, Ssa Ag promoted in vitro TNBC cell apoptosis and restrained cell growth, and repressed in vivo tumor growth.

Conclusions. Ssa Ag inhibited TNBC progression via upregulating DUSP6 and inactivating the MAPK signaling pathway.

Full Text:

View PDF Download PDF file
Get Citation

Keywords

soyasaponin Ag; DUSP6/MAPK signaling; triple-negative breast cancer; proliferation; apoptosis

About this article
Title

Soyasaponin Ag inhibits triple-negative breast cancer progression via targeting the DUSP6/MAPK signaling

Journal

Folia Histochemica et Cytobiologica

Issue

Vol 59, No 4 (2021)

Article type

Original paper

Pages

291-301

Published online

2021-12-09

Page views

6534

Article views/downloads

628

DOI

10.5603/FHC.a2021.0029

Pubmed

34970732

Bibliographic record

Folia Histochem Cytobiol 2021;59(4):291-301.

Keywords

soyasaponin Ag
DUSP6/MAPK signaling
triple-negative breast cancer
proliferation
apoptosis

Authors

Shoucheng Huang
Ping Huang
Huazhang Wu
Song Wang
Guodong Liu

References (55)
  1. Fahad Ullah M. Breast Cancer: Current Perspectives on the Disease Status. Adv Exp Med Biol. 2019; 1152: 51–64.
    CrossRefPubMed
  2. Ghoncheh M, Pournamdar Z, Salehiniya H. Incidence and Mortality and Epidemiology of Breast Cancer in the World. Asian Pac J Cancer Prev. 2016; 17(S3): 43–46.
    CrossRefPubMed
  3. Kolak A, Kamińska M, Sygit K, et al. Primary and secondary prevention of breast cancer. Ann Agric Environ Med. 2017; 24(4): 549–553.
    CrossRefPubMed
  4. Carey LA, Dees EC, Sawyer L, et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res. 2007; 13(8): 2329–2334.
    CrossRefPubMed
  5. Sheng X, Dai H, Du Y, et al. LncRNA CARMN overexpression promotes prognosis and chemosensitivity of triple negative breast cancer via acting as miR143-3p host gene and inhibiting DNA replication. J Exp Clin Cancer Res. 2021; 40(1): 205.
    CrossRefPubMed
  6. Boyle P. Triple-negative breast cancer: epidemiological considerations and recommendations. Ann Oncol. 2012; 23 Suppl 6: vi7–v12.
    CrossRefPubMed
  7. Stevens KN, Vachon CM, Couch FJ. Genetic susceptibility to triple-negative breast cancer. Cancer Res. 2013; 73(7): 2025–2030.
    CrossRefPubMed
  8. De Cicco P, Catani MV, Gasperi V, et al. Nutrition and Breast Cancer: A Literature Review on Prevention, Treatment and Recurrence. Nutrients. 2019; 11(7).
    CrossRefPubMed
  9. Liyanage PY, Hettiarachchi SD, Zhou Y, et al. Nanoparticle-mediated targeted drug delivery for breast cancer treatment. Biochim Biophys Acta Rev Cancer. 2019; 1871(2): 419–433.
    CrossRefPubMed
  10. Yang SH, Tsatsakis AM, Tzanakakis G, et al. Soyasaponin Ag inhibits α‑MSH‑induced melanogenesis in B16F10 melanoma cells via the downregulation of TRP‑2. Int J Mol Med. 2017; 40(3): 631–636.
    CrossRefPubMed
  11. Kamo S, Suzuki S, Sato T. The content of soyasaponin and soyasapogenol in soy foods and their estimated intake in the Japanese. Food Sci Nutr. 2014; 2(3): 289–297.
    CrossRefPubMed
  12. Tsai WT, Nakamura Y, Akasaka T, et al. Soyasaponin ameliorates obesity and reduces hepatic triacylglycerol accumulation by suppressing lipogenesis in high-fat diet-fed mice. J Food Sci. 2021; 86(5): 2103–2117.
    CrossRefPubMed
  13. Shiraiwa M, Harada K, Okubo K. Composition and structure of "group B saponin" in soybean seed. Agric Biol Chem. 1991; 55(4): 911–917.
    PubMed
  14. Guang C, Chen J, Sang S, et al. Biological functionality of soyasaponins and soyasapogenols. J Agric Food Chem. 2014; 62(33): 8247–8255.
    CrossRefPubMed
  15. Xiao JX, Huang GQ, Zhang SH. Soyasaponins inhibit the proliferation of Hela cells by inducing apoptosis. Exp Toxicol Pathol. 2007; 59(1): 35–42.
    CrossRefPubMed
  16. Yang SH, Ahn EK, Lee JA, et al. Soyasaponins Aa and Ab exert an anti-obesity effect in 3T3-L1 adipocytes through downregulation of PPARγ. Phytother Res. 2015; 29(2): 281–287.
    CrossRefPubMed
  17. Zhang W, Popovich DG. Chemical and biological characterization of oleanane triterpenoids from soy. Molecules. 2009; 14(8): 2959–2975.
    CrossRefPubMed
  18. Hsu CC, Lin TW, Chang WW, et al. Soyasaponin-I-modified invasive behavior of cancer by changing cell surface sialic acids. Gynecol Oncol. 2005; 96(2): 415–422.
    CrossRefPubMed
  19. Omar A, Kalra RS, Putri J, et al. Soyasapogenol-A targets CARF and results in suppression of tumor growth and metastasis in p53 compromised cancer cells. Sci Rep. 2020; 10(1): 6323.
    CrossRefPubMed
  20. Guo YJ, Pan WW, Liu SB, et al. ERK/MAPK signalling pathway and tumorigenesis. Exp Ther Med. 2020; 19(3): 1997–2007.
    CrossRefPubMed
  21. Fang JY, Richardson BC. The MAPK signalling pathways and colorectal cancer. Lancet Oncol. 2005; 6(5): 322–327.
    CrossRefPubMed
  22. Sun QY, Ding LW, Johnson K, et al. SOX7 regulates MAPK/ERK-BIM mediated apoptosis in cancer cells. Oncogene. 2019; 38(34): 6196–6210.
    CrossRefPubMed
  23. Chen L, Wang Y, Luan H, et al. DUSP6 protects murine podocytes from high glucose‑induced inflammation and apoptosis. Mol Med Rep. 2020; 22(3): 2273–2282.
    CrossRefPubMed
  24. Missinato MA, Saydmohammed M, Zuppo DA, et al. Dusp6 attenuates Ras/MAPK signaling to limit zebrafish heart regeneration. Development. 2018; 145(5).
    CrossRefPubMed
  25. Relav L, Estienne A, Price CA. Dual-specificity phosphatase 6 (DUSP6) mRNA and protein abundance is regulated by fibroblast growth factor 2 in sheep granulosa cells and inhibits c-Jun N-terminal kinase (MAPK8) phosphorylation. Mol Cell Endocrinol. 2021; 531: 111297.
    CrossRefPubMed
  26. Wu F, McCuaig RD, Sutton CR, et al. Nuclear-Biased DUSP6 Expression is Associated with Cancer Spreading Including Brain Metastasis in Triple-Negative Breast Cancer. Int J Mol Sci. 2019; 20(12).
    CrossRefPubMed
  27. Muda M, Boschert U, Dickinson R, et al. MKP-3, a novel cytosolic protein-tyrosine phosphatase that exemplifies a new class of mitogen-activated protein kinase phosphatase. J Biol Chem. 1996; 271(8): 4319–4326.
    CrossRefPubMed
  28. Fan MJ, Liang SM, He PJ, et al. Dusp6 inhibits epithelial-mesenchymal transition in endometrial adenocarcinoma via ERK signaling pathway. Radiol Oncol. 2019; 53(3): 307–315.
    CrossRefPubMed
  29. Hsu WC, Chen MY, Hsu SC, et al. DUSP6 mediates T cell receptor-engaged glycolysis and restrains T cell differentiation. Proc Natl Acad Sci U S A. 2018; 115(34): E8027–E8036.
    CrossRefPubMed
  30. James NE, Beffa L, Oliver MT, et al. Inhibition of DUSP6 sensitizes ovarian cancer cells to chemotherapeutic agents via regulation of ERK signaling response genes. Oncotarget. 2019; 10(36): 3315–3327.
    PubMed
  31. Ma R, Ma L, Weng W, et al. DUSP6 SUMOylation protects cells from oxidative damage via direct regulation of Drp1 dephosphorylation. Sci Adv. 2020; 6(13): eaaz0361.
    CrossRefPubMed
  32. Vo AH, Swaggart KA, Woo A, et al. Dusp6 is a genetic modifier of growth through enhanced ERK activity. Hum Mol Genet. 2019; 28(2): 279–289.
    CrossRefPubMed
  33. Yang SH, Le B, Androutsopoulos VP, et al. Anti-inflammatory effects of soyasapogenol I-αa via downregulation of the MAPK signaling pathway in LPS-induced RAW 264.7 macrophages. Food Chem Toxicol. 2018; 113: 211–217.
    CrossRefPubMed
  34. Anbalagan M, Ali A, Jones RK, et al. Peptidomimetic Src/pretubulin inhibitor KX-01 alone and in combination with paclitaxel suppresses growth, metastasis in human ER/PR/HER2-negative tumor xenografts. Mol Cancer Ther. 2012; 11(9): 1936–1947.
    CrossRefPubMed
  35. Luby AO, Subramanian C, Buchman LK, et al. Amifostine Prophylaxis in Irradiated Breast Reconstruction: A Study of Oncologic Safety In Vitro. Ann Plast Surg. 2020; 85(4): 424–429.
    CrossRefPubMed
  36. Wiggins AKA, Kharotia S, Mason JK, et al. α-Linolenic Acid Reduces Growth of Both Triple Negative and Luminal Breast Cancer Cells in High and Low Estrogen Environments. Nutr Cancer. 2015; 67(6): 1001–1009.
    CrossRefPubMed
  37. Yang SH, Tsatsakis AM, Tzanakakis G, et al. Soyasaponin Ag inhibits α‑MSH‑induced melanogenesis in B16F10 melanoma cells via the downregulation of TRP‑2. Int J Mol Med. 2017; 40(3): 631–636.
    CrossRefPubMed
  38. Omar A, Kalra RS, Putri J, et al. Soyasapogenol-A targets CARF and results in suppression of tumor growth and metastasis in p53 compromised cancer cells. Sci Rep. 2020; 10(1): 6323.
    CrossRefPubMed
  39. Góral I, Wojciechowski K. Surface activity and foaming properties of saponin-rich plants extracts. Adv Colloid Interface Sci. 2020; 279: 102145.
    CrossRefPubMed
  40. Güçlü-Ustündağ O, Mazza G. Saponins: properties, applications and processing. Crit Rev Food Sci Nutr. 2007; 47(3): 231–258.
    CrossRefPubMed
  41. Ellington AA, Berhow M, Singletary KW. Induction of macroautophagy in human colon cancer cells by soybean B-group triterpenoid saponins. Carcinogenesis. 2005; 26(1): 159–167.
    CrossRefPubMed
  42. Ellington AA, Berhow MA, Singletary KW. Inhibition of Akt signaling and enhanced ERK1/2 activity are involved in induction of macroautophagy by triterpenoid B-group soyasaponins in colon cancer cells. Carcinogenesis. 2006; 27(2): 298–306.
    CrossRefPubMed
  43. Hsu CC, Lin TW, Chang WW, et al. Soyasaponin-I-modified invasive behavior of cancer by changing cell surface sialic acids. Gynecol Oncol. 2005; 96(2): 415–422.
    CrossRefPubMed
  44. Lee IA, Park YJ, Joh EH, et al. Soyasaponin Ab ameliorates colitis by inhibiting the binding of lipopolysaccharide (LPS) to Toll-like receptor (TLR)4 on macrophages. J Agric Food Chem. 2011; 59(24): 13165–13172.
    CrossRefPubMed
  45. Pei Y, Zhao H, Du X, et al. [Apoptosis effects on human esophageal cancer cells by soyasaponin Bb and its machanism]. Wei Sheng Yan Jiu. 2010; 39(4): 444–446.
    PubMed
  46. Bermudez O, Pagès G, Gimond C. The dual-specificity MAP kinase phosphatases: critical roles in development and cancer. Am J Physiol Cell Physiol. 2010; 299(2): C189–C202.
    CrossRefPubMed
  47. Hu X, Tang Z, Ma S, et al. Tripartite motif-containing protein 7 regulates hepatocellular carcinoma cell proliferation via the DUSP6/p38 pathway. Biochem Biophys Res Commun. 2019; 511(4): 889–895.
    CrossRefPubMed
  48. Keyse SM. Dual-specificity MAP kinase phosphatases (MKPs) and cancer. Cancer Metastasis Rev. 2008; 27(2): 253–261.
    CrossRefPubMed
  49. Zhang Q, Fan XY, Guo WL, et al. The protective mechanisms of macroalgae Laminaria japonica consumption against lipid metabolism disorders in high-fat diet-induced hyperlipidemic rats. Food Funct. 2020; 11(4): 3256–3270.
    CrossRefPubMed
  50. Ramkissoon A, Chaney KE, Milewski D, et al. Targeted Inhibition of the Dual Specificity Phosphatases DUSP1 and DUSP6 Suppress MPNST Growth via JNK. Clin Cancer Res. 2019; 25(13): 4117–4127.
    CrossRefPubMed
  51. Song H, Wu C, Wei C, et al. Silencing of DUSP6 gene by RNAi-mediation inhibits proliferation and growth in MDA-MB-231 breast cancer cells: an in vitro study. Int J Clin Exp Med 2015. 8(7): p. : 10481–90.
  52. Wu X, Chen S, Lu C. Amyloid precursor protein promotes the migration and invasion of breast cancer cells by regulating the MAPK signaling pathway. Int J Mol Med. 2020; 45(1): 162–174.
    CrossRefPubMed
  53. Park S, Han SH, Kim HG, et al. PRPF4 is a novel therapeutic target for the treatment of breast cancer by influencing growth, migration, invasion, and apoptosis of breast cancer cells via p38 MAPK signaling pathway. Mol Cell Probes. 2019; 47: 101440.
    CrossRefPubMed
  54. Nokin MJ, Bellier J, Durieux F, et al. Methylglyoxal, a glycolysis metabolite, triggers metastasis through MEK/ERK/SMAD1 pathway activation in breast cancer. Breast Cancer Res. 2019; 21(1): 11.
    CrossRefPubMed
  55. Yang SH, Le B, Androutsopoulos VP, et al. Anti-inflammatory effects of soyasapogenol I-αa via downregulation of the MAPK signaling pathway in LPS-induced RAW 264.7 macrophages. Food Chem Toxicol. 2018; 113: 211–217.
    CrossRefPubMed

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By VM Media Group sp z o.o., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl